These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32655270)

  • 21. Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids.
    Luo S; Chu J; Huang H; Yao K
    Biomed Res Int; 2018; 2018():9804582. PubMed ID: 30009181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports.
    Jiang M; Wang L; Du X; Hao M; Gao P
    J Int Med Res; 2020 Sep; 48(9):300060520961916. PubMed ID: 32993424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
    Membreno F; Baez AL; Pandula R; Walser E; Lau DT
    J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower-Extremity Edema Is Common after Transjugular Intrahepatic Portosystemic Shunt Creation and Is Associated with Lower Survival: A Two-Institution Study.
    Rostambeigi N; Farsad K; Young S; Shrestha P; Jahangiri Y; Liang KW; Cretcher M; Golzarian J
    Radiology; 2021 Jan; 298(1):221-227. PubMed ID: 33201792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
    Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
    Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of the curative effect of transjugular intrahepatic portosystemic shunt with expanded polytetrafluoroethylene-covered stent and drug combined with gastroscopy as the secondary prevention of esophageal -gastric variceal bleeding in portal hypertension].
    Lin ZP; Chen SL; Wang JY; Liu F; Tan Q; Peng QF; Zhao JB
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):672-678. PubMed ID: 32911906
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of initial stent position on patency of transjugular intrahepatic portosystemic shunt.
    Luo SH; Chu JG; Huang H; Yao KC
    World J Gastroenterol; 2017 Jul; 23(26):4779-4787. PubMed ID: 28765699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience.
    Kraglund F; Jepsen P; Amanavicius N; Aagaard NK
    Scand J Gastroenterol; 2019 Jul; 54(7):899-904. PubMed ID: 31203699
    [No Abstract]   [Full Text] [Related]  

  • 29. Transjugular intrahepatic portosystemic shunt (TIPS) placement: A comparison of outcomes between patients with hepatic hydrothorax and patients with refractory ascites.
    Young S; Bermudez J; Zhang L; Rostambeigi N; Golzarian J
    Diagn Interv Imaging; 2019 May; 100(5):303-308. PubMed ID: 30522911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation--role of transjugular intrahepatic portosystemic shunt (TIPS).
    Zenz T; Rössle M; Bertz H; Siegerstetter V; Ochs A; Finke J
    Liver; 2001 Feb; 21(1):31-6. PubMed ID: 11169070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
    Garcia-Tsao G
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
    Saad WE; Darwish WM; Davies MG; Waldman DL
    J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.
    Zhuge YZ; Wang Y; Zhang F; Zhu CK; Zhang W; Zhang M; He Q; Yang J; He J; Chen J; Zou XP
    Liver Int; 2018 Oct; 38(10):1867-1874. PubMed ID: 29297975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transjugular liver biopsy after transjugular intrahepatic portosystemic shunt (TIPS) or direct intrahepatic portocaval shunt (DIPS): Is it feasible, effective, and safe?
    Kaufman C; Aryafar H; Minocha J; Kinney T
    Diagn Interv Imaging; 2018 May; 99(5):331-335. PubMed ID: 29366793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of the efficacy of TIPS in 27 patients with hepatic sinus obstruction syndrome in the near and medium term].
    Wang L; Zhang Y; Wang XQ; Yue ZD; Fan ZH; Wu YF; Liu FQ; Dong J; Zhang K; Jiang L; Ding HG; Zhang YN
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):842-846. PubMed ID: 37723066
    [No Abstract]   [Full Text] [Related]  

  • 38. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.
    Sahagun G; Benner KG; Saxon R; Barton RE; Rabkin J; Keller FS; Rosch J
    Am J Gastroenterol; 1997 Sep; 92(9):1444-52. PubMed ID: 9317060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tusanqi and hepatic sinusoidal obstruction syndrome.
    Wang JY; Gao H
    J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy
    Jiang TT; Luo XP; Sun JM; Gao J
    World J Gastroenterol; 2017 Nov; 23(41):7470-7477. PubMed ID: 29151701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.